WO2015161044A1 - Signature transcriptionnelle pour maladie ...,https://www.google.com/patents/WO2015161044A1?cl=fr
"WO2009046824A2 - Use of apelin-12 as a therapeutic agent, eg for ...",https://www.google.com/patents/WO2009046824A2
WO2016170348A2 - Sarna compositions and methods of use ...,https://www.google.com/patents/WO2016170348A2?cl=ru
US20120004928A1 - System and method for most rapidly procuring ...,https://www.google.com/patents/US20120004928
WO2009046874A1 - Therapeutic combination of trh-potentiating ...,https://www.google.com/patents/WO2009046874A1?cl=pt
EP2190453A2 - Utilisation de la trp6-triptor√©line et du d-leu6 ...,https://www.google.com/patents/EP2190453A2?cl=fr
EP2187940B1 - Use of urocortin optionally together with ...,https://www.google.com/patents/EP2187940B1?cl=da
WO2009046877A2 - Use of a histrelin and leuprolide as therapeutic ...,https://www.google.com/patents/WO2009046877A2?cl=pt
CA2699107A1 - Use of a platelet fibrinogen receptor hexapeptide ...,https://www.google.com/patents/CA2699107A1?cl=enIt
CA2698770A1 - Use of secretin and optionally urodilatin as a ...,https://www.google.com/patents/CA2698770A1?cl=ko
